<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0018">
 <label>18</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Palmieri</surname>
    <given-names>C</given-names>
   </name>, 
   <name name-style="western">
    <surname>Stein</surname>
    <given-names>RC</given-names>
   </name>, 
   <name name-style="western">
    <surname>Liu</surname>
    <given-names>X</given-names>
   </name>
  </person-group>, 
  <person-group person-group-type="editor">
   <etal>et al.</etal>
  </person-group>
  <article-title>IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients</article-title>. 
  <source>Breast Cancer Res Treat</source>
  <year>2017</year>;
  <volume>165</volume>:
  <fpage>343</fpage>–
  <lpage>53</lpage>.
  <pub-id pub-id-type="pmid">28612226</pub-id>
 </mixed-citation>
</ref>
